| scholarly article | Q13442814 |
| P50 | author | Leonard B. Saltz | Q37830465 |
| Jinru Shia | Q39514846 | ||
| P2093 | author name string | Muhammad Wasif Saif | |
| David B Solit | |||
| Efsevia Vakiani | |||
| Ellen Hollywood | |||
| Marwan G Fakih | |||
| Jonathan Schwartz | |||
| Hagop Youssoufian | |||
| Kumari Chandrawansa | |||
| Aruna Dontabhaktuni | |||
| Diane Lauren Reidy | |||
| Joel Randolph Hecht | |||
| Noah Goodman-Davis | |||
| P2860 | cites work | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 |
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. | Q33196244 | ||
| A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes | Q33541323 | ||
| Structure and function of the type 1 insulin-like growth factor receptor. | Q34015458 | ||
| The role of the IGF system in cancer: from basic to clinical studies and clinical applications | Q34157884 | ||
| Insulin-like growth factors and neoplasia. | Q34330521 | ||
| Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis | Q34790667 | ||
| Insulin-like growth factor receptor as a therapeutic target in head and neck cancer | Q40106645 | ||
| Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib | Q40138493 | ||
| Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma | Q40228567 | ||
| In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors | Q40433669 | ||
| Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. | Q44295790 | ||
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. | Q55043614 | ||
| High-throughput oncogene mutation profiling in human cancer | Q57693480 | ||
| BRAFMutation in Metastatic Colorectal Cancer | Q61481269 | ||
| Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone | Q81629286 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| colorectal cancer | Q188874 | ||
| preproinsulin | Q7240673 | ||
| cetuximab | Q420296 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 4240-4246 | |
| P577 | publication date | 2010-08-16 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer | |
| P478 | volume | 28 |
| Q30316105 | A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer |
| Q35682599 | A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. |
| Q37029389 | A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal |
| Q39372420 | A new design immunotoxin for killing high-grade glioma U87 cells: from in vitro to in vivo |
| Q33405880 | A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer |
| Q40298545 | A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel |
| Q35982635 | A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer |
| Q35000503 | A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer |
| Q90702699 | A systematic review of salvage therapies in refractory metastatic colorectal cancer |
| Q33436873 | Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis |
| Q35612939 | Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody |
| Q38219290 | Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories |
| Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
| Q38118934 | Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance |
| Q34323991 | Antibody phage display libraries: contributions to oncology. |
| Q39763068 | BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients |
| Q34336988 | Can we unlock the potential of IGF-1R inhibition in cancer therapy? |
| Q38002127 | Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. |
| Q26769958 | Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer |
| Q38342378 | Clinical impact of studying epithelial-mesenchymal plasticity in pluripotent stem cells |
| Q37230631 | Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway |
| Q36257068 | Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma |
| Q90699218 | Comprehensive review of targeted therapy for colorectal cancer |
| Q30313824 | Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. |
| Q39051582 | Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. |
| Q37970537 | Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer |
| Q42579657 | Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance |
| Q26777704 | Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis |
| Q36019729 | Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell |
| Q37893414 | Emerging antibody combinations in oncology |
| Q34104101 | Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy |
| Q26827810 | Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. |
| Q26822011 | From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors |
| Q37326863 | Future of targeted agents in metastatic colorectal cancer |
| Q44513878 | Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial |
| Q39457320 | Generation of a conditionally transformed murine embryonic fibroblast cell line using doxycycline-dependent IGF-1R overexpression |
| Q41511106 | IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. |
| Q34110523 | Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma |
| Q38990201 | Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link |
| Q37047067 | Insulin-like growth factor: current concepts and new developments in cancer therapy |
| Q36100844 | KRAS mutant colorectal tumors: past and present |
| Q24598640 | Markers of resistance to anti-EGFR therapy in colorectal cancer |
| Q28074073 | Mechanisms of resistance to anti-EGFR therapy in colorectal cancer |
| Q36859958 | Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma |
| Q33909084 | Nanoways to overcome docetaxel resistance in prostate cancer |
| Q36562098 | Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents |
| Q39151211 | Novel biotechnology approaches in colorectal cancer diagnosis and therapy |
| Q90596253 | Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment |
| Q58614590 | Optimal use of EGFR inhibitors: challenges, new drugs and future directions |
| Q38071119 | Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. |
| Q27853128 | Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. |
| Q34731381 | Personalized colon cancer care in 2010. |
| Q34273411 | Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics |
| Q37121517 | Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer |
| Q35226507 | Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors |
| Q90292848 | Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer |
| Q38395821 | Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas |
| Q37875054 | Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer |
| Q37658881 | Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer |
| Q35212113 | Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer |
| Q55002072 | Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. |
| Q42854245 | Rational engineering of antibody therapeutics targeting multiple oncogene pathways |
| Q37850852 | Recent advances in understanding the role of diet and obesity in the development of colorectal cancer. |
| Q30238760 | Second-line systemic therapy for metastatic colorectal cancer. |
| Q46300809 | Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. |
| Q38074430 | Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? |
| Q38096413 | Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine |
| Q35677049 | Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer |
| Q36708178 | Targeting the insulin-like growth factor-1 receptor in human cancer |
| Q26777125 | The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy |
| Q27000467 | The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy |
| Q35030616 | The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin |
| Q35209365 | The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma |
| Q27013945 | The insulin-like growth factor system in cancer |
| Q34625578 | Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. |
| Q38003074 | Translation of molecular pathways into clinical trials of neuroendocrine tumors |
| Q38115675 | Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis |
| Q37702186 | Type I insulin-like growth factor receptor signaling in hematological malignancies |
| Q31038305 | Where now for anti-EGF receptor therapies in colorectal cancer? |
| Q37138970 | XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer |
Search more.